Pfizer-BioNTech COVID-19 vaccine triggers a response in opposition to key mutations

Results from an in vitro study suggest that antibodies raised from the vaccine against Pfizer BioNTech Coronavirus Disease 2019 (COVID-19) are severe coronavirus 2 (SARS-CoV-2) with acute respiratory syndrome with the mutation associated with rapid transmission can effectively neutralize.

The study was conducted by Pfizer and the University of Texas Medical Department to see if sera from people vaccinated with the Pfizer BioNTech mRNA vaccine BNT162b2 could neutralize SARS-CoV-2 with the N501Y mutation. Twenty samples were tested, all of which neutralized the virus with and without mutation. The results show that the N501Y mutation found in the UK and South Africa variants does not appear to produce resistance to BNT162b2-induced immune responses.

The researchers found that while these early in vitro findings are encouraging, more data is needed to determine the vaccine’s effectiveness against preventing COVID-19 disease caused by new virus variants. More information about the study can be found here.

The BNT162b2 vaccine is administered intramuscularly as a 2-dose series (0.3 ml each) with an interval of 21 days. In December, the Food and Drug Administration approved BNT162b2 for emergency use for active immunization to prevent COVID-19 in people aged 16 and over.


An in vitro study shows that the Pfizer-BioNTech COVID-19 vaccine elicits antibodies that neutralize SARS-CoV-2 with a mutation associated with rapid transmission. [press release]. New York, NY and Mainz, Germany: Pfizer and BioNTech; January 8, 2021.

This article originally appeared on MPR


COVID19 General Infectious Disease General Neurology Practice Management Airways

Related Articles